دورية أكاديمية
أعرض في EDS

Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins.

التفاصيل البيبلوغرافية
العنوان: Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins.
المؤلفون: Phung MT; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan., Lee AW; Department of Public Health, California State University, Fullerton, Fullerton, California., Wu AH; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California., Berchuck A; Division of Gynecologic Oncology, Duke University School of Medicine, Durham, North Carolina., Cho KR; Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan., Cramer DW; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, Massachusetts.; Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Doherty JA; Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah., Goodman MT; Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, California., Hanley GE; Department of Obstetrics and Gynecology, University of British Columbia Faculty of Medicine, Vancouver, Canada., Harris HR; Division of Public Health Sciences, Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, Washington., McLean K; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, Michigan., Modugno F; Women's Cancer Research Center, Magee-Women's Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania.; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Moysich KB; Division of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York., Mukherjee B; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan., Schildkraut JM; Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia., Terry KL; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, Massachusetts.; Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Titus LJ, Jordan SJ; University of Queensland, School of Public Health, Brisbane, Queensland, Australia., Webb PM, Pike MC; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Pearce CL
مؤلفون مشاركون: Ovarian Cancer Association Consortium, Australian Ovarian Cancer Study Group and the Ovarian Cancer Association Consortium, Ovarian Cancer Association Consortium
المصدر: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2021 May; Vol. 30 (5), pp. 927-935. Date of Electronic Publication: 2021 Feb 22.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9200608 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7755 (Electronic) Linking ISSN: 10559965 NLM ISO Abbreviation: Cancer Epidemiol Biomarkers Prev Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : American Association for Cancer Research, c1991-
مواضيع طبية MeSH: Carcinoma, Ovarian Epithelial/*prevention & control , Contraceptive Agents, Hormonal/*administration & dosage , Medroxyprogesterone Acetate/*administration & dosage , Ovarian Neoplasms/*prevention & control, Adult ; Carcinoma, Ovarian Epithelial/epidemiology ; Case-Control Studies ; Female ; Humans ; Middle Aged ; Ovarian Neoplasms/epidemiology ; Progestins/pharmacology ; Risk Assessment
مستخلص: Background: Combined oral contraceptive use is associated with a decreased risk of invasive epithelial ovarian cancer (ovarian cancer). There is suggestive evidence of an inverse association between progestin-only contraceptive use and ovarian cancer risk, but previous studies have been underpowered.
Methods: The current study used primary data from 7,977 women with ovarian cancer and 11,820 control women in seven case-control studies from the Ovarian Cancer Association Consortium to evaluate the association between use of depot-medroxyprogesterone acetate (DMPA), an injectable progestin-only contraceptive, and ovarian cancer risk. Logistic models were fit to determine the association between ever use of DMPA and ovarian cancer risk overall and by histotype. A systematic review of the association between DMPA use and ovarian cancer risk was conducted.
Results: Ever use of DMPA was associated with a 35% decreased risk of ovarian cancer overall (OR, 0.65; 95% confidence interval, 0.50-0.85). There was a statistically significant trend of decreasing risk with increasing duration of use ( P trend < 0.001). The systematic review yielded six studies, four of which showed an inverse association and two showed increased risk.
Conclusions: DMPA use appears to be associated with a decreased risk of ovarian cancer in a duration-dependent manner based on the preponderance of evidence. Further study of the mechanism through which DMPA use is associated with ovarian cancer is warranted.
Impact: The results of this study are of particular interest given the rise in popularity of progestin-releasing intrauterine devices that have a substantially lower progestin dose than that in DMPA, but may have a stronger local effect.
(©2021 American Association for Cancer Research.)
References: Obstet Gynecol Clin North Am. 2007 Mar;34(1):91-111, ix. (PMID: 17472867)
JAMA. 1983 Jun 3;249(21):2909-12. (PMID: 6842804)
Epidemiology. 2008 Mar;19(2):237-43. (PMID: 18223481)
PLoS One. 2010 Apr 08;5(4):e10061. (PMID: 20386703)
Int J Cancer. 2008 Jan 1;122(1):170-6. (PMID: 17721999)
Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2548-56. (PMID: 18086757)
Syst Rev. 2016 Dec 5;5(1):210. (PMID: 27919275)
Gynecol Oncol. 2018 Apr;149(1):127-132. (PMID: 29482839)
J Cell Biochem. 2001;82(3):445-51. (PMID: 11500921)
Oncogene. 2003 Oct 9;22(44):6883-90. (PMID: 14534535)
Int J Cancer. 1991 Sep 9;49(2):191-5. (PMID: 1831803)
Fertil Steril. 2004 Jul;82(1):186-95. (PMID: 15237010)
Int J Cancer. 2009 Mar 15;124(6):1409-15. (PMID: 19065661)
J Reprod Med. 1996 May;41(5 Suppl):381-90. (PMID: 8725700)
Cancer Causes Control. 2017 May;28(5):487-495. (PMID: 28283879)
BMJ. 2018 Sep 26;362:k3609. (PMID: 30257920)
J Clin Endocrinol Metab. 1977 Jan;44(1):32-8. (PMID: 833262)
BJOG. 2012 May;119(6):672-7. (PMID: 22489761)
Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):880-90. (PMID: 23462924)
J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86. (PMID: 9839517)
Cancer Causes Control. 2013 Dec;24(12):2197-206. (PMID: 24077761)
Int J Cancer. 2015 Aug 1;137(3):607-14. (PMID: 25556333)
Contraception. 2009 Oct;80(4):391-408. (PMID: 19751863)
Cell Rep. 2017 Mar 14;18(11):2557-2565. (PMID: 28297660)
Lancet. 2008 Jan 26;371(9609):303-14. (PMID: 18294997)
Am J Epidemiol. 1994 Apr 1;139(7):654-61. (PMID: 8166126)
Obstet Gynecol. 2007 Mar;109(3):597-607. (PMID: 17329510)
Contraception. 2004 Jul;70(1):11-8. (PMID: 15208047)
Acta Oncol. 2016 Nov;55(11):1281-1284. (PMID: 27148621)
Cancer Prev Res (Phila). 2019 Jun;12(6):401-412. (PMID: 31015198)
Contraception. 1980 Nov;22(5):527-36. (PMID: 6451351)
PLoS Med. 2012;9(3):e1001182. (PMID: 22412354)
Epidemiology. 2012 Mar;23(2):311-9. (PMID: 22252409)
N Engl J Med. 1987 Mar 12;316(11):650-5. (PMID: 3821795)
Cancer Res. 2005 Jul 1;65(13):5974-81. (PMID: 15994977)
Endocr Rev. 2013 Apr;34(2):171-208. (PMID: 23238854)
Natl Health Stat Report. 2013 Feb 14;(62):1-15. (PMID: 24988816)
Cancer. 1997 May 15;79(10):1944-50. (PMID: 9149021)
معلومات مُعتمدة: R01 CA136891 United States CA NCI NIH HHS; R01 CA087538 United States CA NCI NIH HHS; P50 CA105009 United States CA NCI NIH HHS; K07 CA080668 United States CA NCI NIH HHS; P30 CA008748 United States CA NCI NIH HHS; R03 CA115195 United States CA NCI NIH HHS; R01 CA054419 United States CA NCI NIH HHS; R01 CA076016 United States CA NCI NIH HHS; P01 CA017054 United States CA NCI NIH HHS; R01 CA112523 United States CA NCI NIH HHS; R01 CA126841 United States CA NCI NIH HHS; N01 CN025403 United States CN NCI NIH HHS; N01 PC067010 United States PC NCI NIH HHS; P50 CA159981 United States CA NCI NIH HHS; P30 CA046592 United States CA NCI NIH HHS; M01 RR000056 United States RR NCRR NIH HHS; R01 CA095023 United States CA NCI NIH HHS; R03 CA113148 United States CA NCI NIH HHS; R01 CA058598 United States CA NCI NIH HHS; P30 CA014089 United States CA NCI NIH HHS; R01 AG061132 United States AG NIA NIH HHS
المشرفين على المادة: 0 (Contraceptive Agents, Hormonal)
0 (Progestins)
C2QI4IOI2G (Medroxyprogesterone Acetate)
تواريخ الأحداث: Date Created: 20210223 Date Completed: 20220112 Latest Revision: 20240615
رمز التحديث: 20240615
مُعرف محوري في PubMed: PMC9281627
DOI: 10.1158/1055-9965.EPI-20-1355
PMID: 33619020
قاعدة البيانات: MEDLINE
الوصف
تدمد:1538-7755
DOI:10.1158/1055-9965.EPI-20-1355